Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
PT

NASDAQ · PTGX

Protagonist Therapeutics, Inc.

Healthcare · Biotechnology

$145.16

Up+$0.07 (+0.05%)

Updated Sep 11, 2026, 7:31 AM

SID Score

5.4/10

Composite research score

Smart Money

56/100

Neutral

Market cap
5.77B
P/E ratio
128.14
Dividend yield
0.00%
52-week range
$90.58 – $160.81
Volume
543.13K
Avg. volume
1.18M

Price performance

PTGX price history

1M range · 20 trading sessions · Daily adjusted prices

PTGX closed at $145.16 after 20 trading sessions, down 4.13% for the selected period.

Last close
$145.16
Period change
-4.13%
Period low
$144.33
Period high
$158.62
Daily close
View OHLC price history
PTGX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$143.29$146.51$142.00$145.16543.13K
Sep 9, 2026$146.05$151.185$144.46$145.09530.53K
Sep 8, 2026$143.61$147.29$142.00$145.94700.13K
Sep 4, 2026$146.47$147.99$144.01$145.72501.31K
Sep 3, 2026$146.68$149.49$144.0001$148.80354.19K
Sep 2, 2026$148.00$149.42$144.61$146.08561.61K
Sep 1, 2026$147.75$150.34$144.725$146.49534.14K
Aug 31, 2026$143.26$149.295$141.9479$147.75567.4K
Aug 28, 2026$147.73$147.95$142.43$144.33501.25K
Aug 27, 2026$150.35$151.68$147.11$149.50381.59K
Aug 26, 2026$150.36$152.07$147.69$151.50335.46K
Aug 25, 2026$155.84$157.98$150.09$150.59664.53K
Aug 24, 2026$154.32$158.08$149.94$154.72483.34K
Aug 21, 2026$152.10$154.95$150.82$154.32402.54K
Aug 20, 2026$152.45$155.25$148.275$150.69518.56K
Aug 19, 2026$160.81$160.81$154.22$154.94786.05K
Aug 18, 2026$157.96$160.00$156.81$157.34471.65K
Aug 17, 2026$155.11$158.95$153.60$158.62506.96K
Aug 14, 2026$150.23$155.53$149.17$155.10426.26K
Aug 13, 2026$153.15$154.99$150.92$151.42444.79K

Latest PTGX news

The latest Smart Investors Daily articles mentioning PTGX.

Stock researchCompany · Overview

PTGX research

Overview

Company profile and research snapshot.

Company profile

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$90.67
Implied upside
—
Analysts
—
PTGX recent ratings
DateFirmRatingTarget
Sep 1, 2026BMO CapitalOutperform—
Sep 1, 2026BarclaysOverweight—
Aug 31, 2026HC Wainwright & Co.Buy—
Aug 31, 2026CitigroupBuy—
Aug 17, 2026BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additional $200 million opt-out fee and a separate $75 million approval milestone. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) chose royalties over the original 50:50 U.S. […]

Yahoo · Sep 1, 2026

Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News

Protagonist Therapeutics stock has delivered very strong returns over the past few years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like an obvious bargain. After such a strong move, investors are weighing how much of the good news is already reflected in the price. Over the past 3 years, Protagonist Therapeutics has gained roughly 6.5 times its earlier level. This puts extra focus on whether recent enthusiasm has pushed the valuation...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By